11.61
0.17 (1.49%)
| 前收盘价格 | 11.44 |
| 收盘价格 | 11.52 |
| 成交量 | 525,933 |
| 平均成交量 (3个月) | 841,233 |
| 市值 | 4,102,938,880 |
| 预期市盈率 (P/E Forward) | 22.32 |
| 价格/销量 (P/S) | 0.890 |
| 股市价格/股市净资产 (P/B) | 0.680 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2025 |
| 营业毛利率 | -7.50% |
| 营业利益率 (TTM) | -5.36% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | 3.50% |
| 总债务/股东权益 (D/E MRQ) | 75.07% |
| 流动比率 (MRQ) | 1.56 |
| 营业现金流 (OCF TTM) | 166.00 M |
| 杠杆自由现金流 (LFCF TTM) | 69.00 M |
| 资产报酬率 (ROA TTM) | 0.61% |
| 股东权益报酬率 (ROE TTM) | -5.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 看跌 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看跌 | 看跌 | |
| 股票 | Bausch + Lomb Corporation | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.90 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Core |
| 内部持股比例 | 88.17% |
| 机构持股比例 | 11.01% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Clearline Capital Lp | 31 Mar 2025 | 893,790 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 17.00 (RBC Capital, 46.43%) | 购买 |
| 中 | 15.00 (29.20%) | |
| 低 | 12.00 (Morgan Stanley, 3.36%) | 保留 |
| 12.00 (Wells Fargo, 3.36%) | 保留 | |
| 平均值 | 14.44 (24.38%) | |
| 总计 | 3 购买, 5 保留 | |
| 平均价格@调整类型 | 11.78 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 09 Jun 2025 | 16.00 (37.81%) | 保留 | 11.98 |
| Morgan Stanley | 06 May 2025 | 12.00 (3.36%) | 保留 | 10.90 |
| HC Wainwright & Co. | 02 May 2025 | 15.00 (29.20%) | 购买 | 11.50 |
| Citigroup | 01 May 2025 | 13.00 (11.97%) | 保留 | 11.59 |
| Evercore ISI Group | 01 May 2025 | 15.50 (33.51%) | 购买 | 11.59 |
| Wells Fargo | 01 May 2025 | 12.00 (3.36%) | 保留 | 11.59 |
| 28 Mar 2025 | 15.00 (29.20%) | 保留 | 14.13 | |
| RBC Capital | 04 Apr 2025 | 17.00 (46.43%) | 购买 | 12.11 |
| Stifel | 03 Apr 2025 | 15.00 (29.20%) | 保留 | 12.99 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BONNEFOY LUC | - | 12.33 | -968 | -11,935 |
| 累积净数量 | -968 | |||
| 累积净值 ($) | -11,935 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 12.33 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BONNEFOY LUC | 职员 | 13 Jun 2025 | 处理 (-) | 968 | 12.33 | 11,935 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合